1 citations,
March 2023 in “Scientific Reports” Finasteride may increase the risk of suicide or severe self-harm in men with mood disorders but not in the general population.
70 citations,
November 2013 in “The BMJ” Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
218 citations,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
1 citations,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
5 citations,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
Autonomous robotic surgery is advancing but still requires human supervision for complex procedures.
2 citations,
October 2000 in “The Journal of Urology” Finasteride daily doesn't affect sperm production or semen in young men.
February 2022 in “Journal of clinical research and reports” Plasma therapy is becoming more popular for treating viral infections, skin conditions, and orthopedic issues, and is expected to grow in the healthcare market.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
3 citations,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
101 citations,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
3 citations,
June 2017 in “The Journal of urology/The journal of urology” Older men with postoperative urinary retention are more likely to need future bladder procedures.
18 citations,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
10 citations,
February 2009 in “European urology. Supplement” Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
April 2024 in “Journal of cancer research and clinical oncology” Tissue-derived extracellular vesicles are crucial for cancer diagnosis, prognosis, and treatment.
9 citations,
August 2019 in “Clinical genitourinary cancer” Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
28 citations,
August 2011 in “Journal of The American Academy of Dermatology” Early hair loss may indicate prostate issues.
4 citations,
August 2021 in “Annals of Translational Medicine” Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
1707 citations,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
11 citations,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
6 citations,
September 1997 in “Prostate Cancer and Prostatic Diseases” Finasteride 5 mg effectively reduces urinary symptoms and PSA levels in men with enlarged prostates, with few sexual side effects.
3 citations,
February 2016 in “Scandinavian journal of urology” Finasteride use varies among Denmark, Finland, Norway, and Sweden, with higher usage in Finland and Sweden.
Finasteride is popular for treating male hair loss but may increase the risk of serious prostate cancer and has other potential side effects.
11 citations,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
1054 citations,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
90 citations,
January 2003 in “The Journal of Urology” Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.
21 citations,
April 1998 in “Urology” Finasteride effectively treats BPH and hair loss but may cause sexual side effects.